Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Adrian J. Haigh Buys 22,222 Shares

Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Adrian J. Haigh bought 22,222 shares of the stock in a transaction on Monday, April 15th. The shares were acquired at an average cost of C$2.31 per share, with a total value of C$51,332.82.

Fennec Pharmaceuticals Stock Down 3.8 %

TSE:FRX opened at C$13.77 on Friday. The company has a quick ratio of 10.17, a current ratio of 3.29 and a debt-to-equity ratio of 881.09. Fennec Pharmaceuticals Inc. has a 12-month low of C$9.27 and a 12-month high of C$15.43. The stock’s fifty day simple moving average is C$13.52 and its 200-day simple moving average is C$12.63. The firm has a market capitalization of C$372.34 million, a P/E ratio of -13.50 and a beta of 0.35.

Fennec Pharmaceuticals (TSE:FRX) last issued its earnings results on Thursday, March 21st. The biopharmaceutical company reported C($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of C$0.02 by C($0.16). The company had revenue of C$13.25 million for the quarter, compared to the consensus estimate of C$12.88 million. Fennec Pharmaceuticals had a negative return on equity of 1,005.59% and a negative net margin of 75.50%. Equities research analysts expect that Fennec Pharmaceuticals Inc. will post 0.4202312 earnings per share for the current year.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.